Skip to main content
Evidence Snapshot

Fibroblast growth factor receptor 1

CHEMBL3650 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:40Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3650
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fibroblast growth factor receptor 1 as ChEMBL target CHEMBL3650, mapped to UniProt P11362. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Fibroblast growth factor receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3650
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P11362
Fibroblast growth factor receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Fibroblast growth factor receptor 1 matters

As of 2026-09-14

Fibroblast growth factor receptor 1 is reviewed as Fibroblast growth factor receptor 1 (UniProt P11362); Fibroblast growth factor receptor 1 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 9 linked drugs keep this evidence frame grounded.; the current evidence base includes 36 approved drugs, 8313 compounds, and 1252 assays, with lead potency reaching pChEMBL 10.0.

Disease context
neoplasm

Fibroblast growth factor receptor 1 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include E-7090, FGFR INHIBITOR DEBIO 1347, HMPL-453.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include E-7090, FGFR INHIBITOR DEBIO 1347, HMPL-453, LUCITANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 9 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 36 approved drugs, 8313 compounds, and 1252 assays for this target. The dominant activity type is IC50. CHEMBL5951244 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL5951244 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
36 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Fibroblast growth factor receptor 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P11362, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

8313
Total Compounds
1252
Total Assays
36
Approved Drugs
IC50: 8986.0, KI: 1233.0, EC50: 43.0, KD: 419.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5951244
 10.0 IC50 —
No preferred name
CHEMBL4870179
 9.9 IC50 —
No preferred name
CHEMBL4862823
 9.8 IC50 —
No preferred name
CHEMBL5177696
 9.7 IC50 —
No preferred name
CHEMBL5556891
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
CAPIVASERTIB
CHEMBL2325741
 2023
FUTIBATINIB
CHEMBL3701238
 2022
INFIGRATINIB PHOSPHATE
CHEMBL1834657
 2021
INFIGRATINIB
CHEMBL1852688
 2021
PEMIGATINIB
CHEMBL4297522
 2020
FEDRATINIB
CHEMBL1287853
 2019
ERDAFITINIB
CHEMBL3545376
 2019
ENTRECTINIB
CHEMBL1983268
 2019
BRIGATINIB
CHEMBL3545311
 2017
TIVOZANIB
CHEMBL1289494
 2017
LENVATINIB
CHEMBL1289601
 2015
NINTEDANIB ESYLATE
CHEMBL3039504
 2014
NINTEDANIB
CHEMBL502835
 2014
REGORAFENIB
CHEMBL1946170
 2012
CABOZANTINIB
CHEMBL2105717
 2012
AXITINIB
CHEMBL1289926
 2012
PONATINIB
CHEMBL1171837
 2012
VANDETANIB
CHEMBL24828
 2011
PAZOPANIB
CHEMBL477772
 2009
SUNITINIB
CHEMBL535
 2006
DASATINIB
CHEMBL5416410
 2006
SORAFENIB
CHEMBL1336
 2005
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:40Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3650